Insider Selling: Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) General Counsel Sells 25,000 Shares of Stock

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the transaction, the general counsel now directly owns 167,618 shares in the company, valued at $843,118.54. The trade was a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Maravai LifeSciences Price Performance

NASDAQ:MRVI traded down $0.12 during trading hours on Friday, hitting $4.93. The company’s stock had a trading volume of 1,413,916 shares, compared to its average volume of 2,121,486. The stock has a fifty day simple moving average of $5.43 and a 200-day simple moving average of $7.18. The company has a market capitalization of $1.24 billion, a P/E ratio of -3.01 and a beta of -0.07. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. Maravai LifeSciences Holdings, Inc. has a twelve month low of $4.28 and a twelve month high of $11.56.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.09) earnings per share (EPS) for the quarter. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The company had revenue of $65.20 million for the quarter, compared to the consensus estimate of $67.58 million. During the same quarter last year, the business earned ($0.02) earnings per share. On average, analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on MRVI shares. Royal Bank of Canada lowered their target price on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Wolfe Research started coverage on shares of Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Robert W. Baird lowered their target price on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. William Blair restated a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th. Finally, Guggenheim initiated coverage on shares of Maravai LifeSciences in a research note on Thursday, December 19th. They set a “neutral” rating for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $10.28.

Institutional Investors Weigh In On Maravai LifeSciences

Hedge funds have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in Maravai LifeSciences in the second quarter worth approximately $32,000. FNY Investment Advisers LLC increased its holdings in Maravai LifeSciences by 600.0% in the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after purchasing an additional 6,000 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in Maravai LifeSciences in the third quarter worth approximately $47,000. Custom Index Systems LLC bought a new stake in Maravai LifeSciences in the third quarter worth approximately $97,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Maravai LifeSciences during the third quarter valued at approximately $105,000. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.